Should I Buy BBIO? BBIO 2026 Analysis

Should You Buy BridgeBio Pharma Inc (BBIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

68.140

1 Day change

-3.65%

52 Week Range

84.940

Analysis Updated At

2026/02/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BridgeBio Pharma Inc (BBIO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as favorable Phase 3 trial results and strong analyst support, the recent price decline and lack of immediate trading signals suggest it is better to wait for further developments, including the upcoming Q4 earnings report on February 24, 2026.

Technical Analysis

The technical indicators show a bearish trend. The MACD is negatively expanding, and the RSI is neutral at 36.206, indicating no clear signal. The stock is trading below its pivot level of 73.316, with key support at 64.874 and resistance at 81.758. Moving averages are converging, suggesting indecision in the market.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Positive Phase 3 trial results for oral infigratinib in achondroplasia, showing significant height velocity improvement.
Analysts have raised price targets, with multiple firms projecting upside potential (e.g., $100 by H.C. Wainwright and Bernstein).
Gross margin improvement to 94.56% in Q3 2025, indicating operational efficiency.

Neutral/Negative Catalysts

Recent price decline of -4.34% in the regular market and -0.20% post-market.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
Concerns over long-term utilization of infigratinib due to potential safety issues (e.g., mild hyperphosphatemia).

Financial Performance

In Q3 2025, revenue increased significantly by 4318.01% YoY to $120.7M, but the company remains unprofitable with a net income of -$182.74M. EPS improved to -0.95, up 10.47% YoY, and gross margin increased to 94.56%, showing strong operational performance despite ongoing losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive, with multiple firms maintaining Buy or Outperform ratings. Price targets range from $83 to $157, reflecting confidence in the company's growth potential driven by its pipeline and recent trial successes.

13 Analyst Rating

Wall Street analysts forecast BBIO stock price to rise

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 70.720

Low

Averages

98.5

High

157

Current: 70.720

Low

Averages

98.5

High

157

H.C. Wainwright

Raghuram Selvaraju

maintain

$90 -> $100

AI Analysis

2026-02-17

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$90 -> $100

AI Analysis

2026-02-17

maintain

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BridgeBio to $100 from $90 and keeps a Buy rating on the shares. The firm cites the positive top-line results from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, for the target boost.

Oppenheimer

Trevor Allred

Outperform

maintain

$81 -> $83

2026-02-13

Reason

Oppenheimer

Trevor Allred

Price Target

$81 -> $83

2026-02-13

maintain

Outperform

Reason

Oppenheimer analyst Trevor Allred raised the firm's price target on BridgeBio to $83 from $81 and keeps an Outperform rating on the shares. The firm says Phase 3 result demonstrated 1.74cm/year least-squares mean AGH improvement, which compares favorably to vosoritide/navepegritide results of 1.5-1.6cm/year, though perhaps incrementally disappoints vs. Propel 2 results. Hyperphosphatemia results may assuage concerns on safety, with only three subjects demonstrating mild, transient hyperphosphatemia, though concerns on long-term utilization may limit total commercial uptake, Oppenheimer adds. The firm considers the results in line with its thesis, and believes efficacy should support infigratinib as best-in-class drug with skewed uptake in the U.S. market vs. ex-U.S.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBIO

Unlock Now

BBIO Should I Buy

BBIO Should I Buy

Should You Buy BridgeBio Pharma Inc (BBIO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch